Source link : https://www.newshealth.biz/health-news/leukemia-drug-shows-promise-in-lewy-body-dementia/
Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved biomarkers and cognitive outcomes in patients with dementia with Lewy bodies (DLB) in a phase 2 randomized, double-blind, placebo-controlled trial. The findings align with an earlier study that showed possible disease-modifying effects of nilotinib in patients with […]
Author : News Health
Publish date : 2024-11-05 14:59:11
Copyright for syndicated content belongs to the linked Source.